Released Mar 31, 2022, before the open
10-K filed Mar 31, 2022, 90 days after period end · 0001558370-22-004823
Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$8.55M$8.55M derived−56.1% vs Q4 2020−29.1% vs Q3 2021
Net Income-$6.67M-$6.67M derivedN/M vs Q4 2020N/M vs Q3 2021
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$5,706,000N/M
Operating Cash Flowderived-$5,087,000N/M
Free Cash Flowderived-$5,535,000N/M
Margins · derived
Operating margin-66.7%−81.3 pt vs Q4 2020
Net margin-78.0%−80.0 pt vs Q4 2020
What the release said
The release
Same quarter
| Metric | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019 | Q4 2018 |
|---|---|---|---|---|
| Revenue | $8.55M | $19.50M | $17.76M | $27.02M |
| Net Income | -$6.67M | $397.00K | $291.00K | -$5.43M |
| EPS Diluted | — | — | $0.02 | -$0.40 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR